PD-011 Safety and efficacy analysis of imalumab, an anti-oxidized macrophage migration inhibitory factor (oxMIF) antibody, alone or in combination with 5-fluorouracil/leucovorin (5-FU/LV) or panitumumab, in patients with metastatic colorectal cancer (mCRC)

Shranjeno v:
Bibliografske podrobnosti
izdano v:Ann Oncol
Main Authors: Mahalingam, D., Patel, M., Sachdev, J., Hart, L., Halama, N., Ramanathan, R., Sarantopoulos, J., Liu, X., Yazji, S., Jäger, D., Adib, D., Kerschbaumer, R., Yoon, M., Manzur, G., Starodub, A., Sivarajan, K., Wertheim, M., Thambi, P., Jones, M., Goel, S., Nemunaitis, J., Tsimberidou, A.
Format: Artigo
Jezik:Inglês
Izdano: Oxford University Press 2016
Teme:
Abstracts
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC4984159/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/annonc/mdw200.11
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki